PubMed_ArguminSci  

PubMed:23457626 JSONTXT 7 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T1 168-320 DRI_Background denotes Pathways involved in DCIS stem and progenitor signalling are poorly understood yet are critical to understand DCIS biology and to develop new therapies.
T2 321-494 DRI_Background denotes Notch and ErbB1/2 receptor signalling cross talk has been demonstrated in invasive breast cancer, but their role in DCIS stem and progenitor cells has not been investigated.
T3 794-855 DRI_Background denotes Western blotting was applied to assess downstream signalling.
T4 856-995 DRI_Outcome denotes In this study we demonstrate that DAPT reduced acini size and mammosphere formation in MCF10DCIS.com whereas there was no effect in SUM225.
T5 996-1143 DRI_Background denotes Lapatinb reduced acini size and mammosphere formation in SUM225, whereas mammosphere formation and Notch1 activity were increased in MCF10DCIS.com.
T6 1144-1244 DRI_Background denotes Combined DAPT/lapatinib treatment was more effective at reducing acini size in both DCIS cell lines.
T7 1245-1396 DRI_Background denotes Mammosphere formation in cell lines and human primary DCIS was reduced further by DAPT/lapatinib or DAPT/gefitinib regardless of ErbB2 receptor status.
T8 1397-1531 DRI_Outcome denotes Our pre-clinical human models of DCIS demonstrate that Notch and ErbB1/2 both play a role in DCIS acini growth and stem cell activity.
T9 1532-1728 DRI_Outcome denotes We report for the first time that cross talk between the two pathways in DCIS occurs regardless of ErbB2 receptor status and inhibition of Notch and ErbB1/2 was more efficacious than either alone.
T10 1729-1917 DRI_Background denotes These data provide further understanding of DCIS biology and suggest treatment strategies combining Notch and ErbB1/2 inhibitors should be investigated regardless of ErbB2 receptor status.